Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens

Prior pharmacokinetic (PK) analyses of the antibody‐drug conjugate (ADC) brentuximab vedotin (1.8 mg/kg every 3 weeks) in pediatric patients with relapsed/refractory hematologic malignancies found that patients aged <12 years exhibited decreased ADC area under the curve (AUC) compared with those...

Descripción completa

Detalles Bibliográficos
Autores principales: Suri, Ajit, Mould, Diane R., Song, Gregory, Kinley, Judith, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689911/
https://www.ncbi.nlm.nih.gov/pubmed/32596842
http://dx.doi.org/10.1002/jcph.1682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689911/
https://www.ncbi.nlm.nih.gov/pubmed/32596842
http://dx.doi.org/10.1002/jcph.1682

Ejemplares similares